Seminars in Hematology
Volume 45 , Pages S25-S29 , July 2008

The Expanding Role of Arsenic in Acute Promyelocytic Leukemia

  • Martin S. Tallman

      Affiliations

    • Corresponding Author InformationAddress correspondence to Martin S. Tallman, MD, Professor of Medicine, Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology, Department of Medicine, 676 N St Clair Street, Suite 850, Chicago, IL 60611-2927

References 

  1. Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, et al. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?. J Clin Oncol. 1999;17:293–297
  2. Montesinos P, De La Serna J, Vellenga E, et al. Clinical features and outcome of patients with acute promyelocytic leukemia presenting CD56 antigen expression treated with the pethema LPA99 trial. Haematol Rep. 2005;1:86;(abstr C20)
  3. Noguera NI, Breccia M, Divona M, Diverio D, Costa V, Santis S, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: Association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16:2185–2189
  4. Gallagher RE, Lee SJ, Sankoorikal B-J, Wiernik PH, Tallman MS. Independent prognostic significant of FLT3 internal tandem duplication (ITD) mutations in acute promyelocytic leukemia (APL) patients treated on ECOG protocol E2491. Blood. 2002;100:326a;(abstr)
  5. Shih LY, Kuo MC, Liang DC, Huding CL, Lin TL, Wu JH, et al. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003;98:1206–1216
  6. Sanz MA, Lo CF, Martin G, Avvisati E, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–1253
  7. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood. 2004;103:1237–1243
  8. Bernard J, Mathe G, Boulay J, Ceoard B, Chome J. [Acute promyelocytic leukemia: A study made on 20 cases.]. Schweiz Med Wochenschr. 1959;89:604–608
  9. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41:489–496
  10. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia. 1994;8:968–973
  11. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia (The European APL Group). Blood. 1999;94:1192–1200
  12. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298–4302
  13. Ades L, Chevret S, Raffoux E, de Bolton S, Guerci A, Pigneux A, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? (Results of a randomized trial from the European Acute Promyelocytic Leukemia Group). J Clin Oncol. 2006;24:5703–5710
  14. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110:59–66
  15. Avvisati G, Petti MC, Lo-Coco F, et al. AIDA: The Italian way of treating acute promyelocytic leukemia (APL), final act. Blood. 2003;102:142a;(abstr 487)
  16. Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia: Updated results of the Spanish PETHEMA LPA99 trial using ATRA and anthracycline monochemotherapy. Blood. 2007;110:182a;(abstr 590)
  17. Lo Coco F, Avvisati G, Vignetti M, Fioritoni G, Liso V, Ferrara F, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: Results of the AIDA-2000 trial of the Italian GIMEMA Group. Blood. 2004;104:115a;(abstr 392)
  18. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffier H, et al. German AML Cooperative Group Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia. 2000;14:1362–1370
  19. Lengfelder E, Saussele S, Haferlach T, et al. Treatment of newly diagnosed acute promyelocytic leukemia: the impact of high dose Ara-C. Blood. 2003;102:142a;(abstr 488)
  20. Powell BL. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. J Clin Oncol. 2007;25:1s;(abstr 2)
  21. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–1061
  22. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852–3860
  23. Shen ZX, Shi ZZ, Fang J, Gu RW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:5328–5335
  24. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469–3473
  25. Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents. 1999;13:195–200
  26. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17:131–134
  27. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood. 2006;107:2627–2632
  28. Combination chemotherapy with or without gemtuzumab followed by tretinoin, mercaptopurine, and methotrexate or observation in treating patients with acute promyelocytic leukemia. http://clinicaltrials.gov/ct2/show/NCT00492856Accessed January 22, 2008
  29. Gemtuzumab and combination chemotherapy in treating patients with previously untreated acute promyelocytic leukemia. http://clinicaltrials.gov/ct2/show/NCT00551460http://clinicaltrials.gov/ct2/show/NCT00492856Accessed January 22, 2008
  30. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997;90:967–973
  31. Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001;97:3919–3924
  32. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res. 2007;67:4524–4532

 STATEMENT OF CONFLICT OF INTEREST: Consultant/Scientific Advisory Board: Cephalon Oncology.

PII: S0037-1963(08)00124-8

doi: 10.1053/j.seminhematol.2008.07.008

Seminars in Hematology
Volume 45 , Pages S25-S29 , July 2008

Article Tools

* Image Usage & Resolution